Henry Schein (HSIC) Stifel Jaws & Paws Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Stifel Jaws & Paws Conference 2026 summary
27 May, 2026Strategic priorities and business transformation
Leadership is focused on delivering on 2026 guidance and value creation initiatives, with progress on both fronts.
Efforts are underway to simplify the business, reduce silos, and better align commercial approaches to enhance customer partnerships.
Growth is being driven by scaling technology and own brands, with a focus on market share gains in distribution.
Accelerated innovation is expected through internal AI development and industry partnerships, especially in technology and specialty products.
Value creation initiatives target $125 million run rate by year-end and up to $200 million over the next few years, emphasizing both gross profit and cost efficiencies.
Market trends and business performance
Dental market remains steady, largely insulated from consumer confidence swings, and is more sensitive to employment rates.
Dental business momentum has continued from Q1 into May, with share gains attributed to promotional activity and experienced sales hires.
Medical segment faced Q1 headwinds from diagnostic test kits, but underlying business showed mid-single-digit growth, expected to continue.
Internationally, Germany and Canada are highlighted as strong performers, with Canada effectively managing competitive challenges.
Internal revenue growth of 2.5% in Q1 is seen as a trough, with expectations for improvement as headwinds subside.
Product innovation and portfolio development
New product launches are accelerating, with a focus on both supplier-driven and internally developed offerings, such as the exclusive Curodont launch.
AI-driven capabilities and cloud-based platforms are being prioritized to increase recurring revenue and customer value.
Specialty products, particularly implants, are a growth focus, with recent majority ownership in a value implant business expected to drive expansion.
Distribution, specialty, and technology businesses are all positioned for above-market growth through expanded offerings and value-added services.
Latest events from Henry Schein
- Record Q3 2025 results, raised guidance, and $200M+ value creation initiatives announced.HSIC
Q3 20258 Jul 2026 - Q2 2024 sales up 1.1% to $3.14B; net income and EPS declined, and guidance was reduced.HSIC
Q2 20248 Jul 2026 - Q4 2024 non-GAAP EPS rose 80% on 5.8% sales growth; 2025 outlook targets steady gains.HSIC
Q4 20248 Jul 2026 - Strategic initiatives and value creation projects drive stable growth and operational efficiency.HSIC
Baird Global Healthcare Conference 20258 Jul 2026 - Leadership changes, all proposals passed, and majority voting adopted for future governance.HSIC
AGM 202621 May 2026 - Strong Q1 growth, margin expansion, and strategic focus position the company for 2026 targets.HSIC
Bank of America Global Healthcare Conference 202613 May 2026 - Board urges support for director nominees and opposes majority vote proposal at annual meeting.HSIC
Proxy filing12 May 2026 - Q1 2026 delivered strong sales, margin, and EPS growth, with guidance and value initiatives reaffirmed.HSIC
Q1 20265 May 2026 - $13.2B FY2025 sales, digital transformation, and high-margin growth drive long-term value.HSIC
Corporate presentation5 May 2026